315 related articles for article (PubMed ID: 27002005)
1. Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.
Hardy T; Zeybel M; Day CP; Dipper C; Masson S; McPherson S; Henderson E; Tiniakos D; White S; French J; Mann DA; Anstee QM; Mann J
Gut; 2017 Jul; 66(7):1321-1328. PubMed ID: 27002005
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome Proliferator-Activated Receptor-γ as a Target and Regulator of Epigenetic Mechanisms in Nonalcoholic Fatty Liver Disease.
Zaiou M
Cells; 2023 Apr; 12(8):. PubMed ID: 37190114
[TBL] [Abstract][Full Text] [Related]
3. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
Murphy SK; Yang H; Moylan CA; Pang H; Dellinger A; Abdelmalek MF; Garrett ME; Ashley-Koch A; Suzuki A; Tillmann HL; Hauser MA; Diehl AM
Gastroenterology; 2013 Nov; 145(5):1076-87. PubMed ID: 23916847
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation patterns of peroxisome proliferator-activated receptor gamma gene associated with liver fibrosis and inflammation in chronic hepatitis B.
Zhao Q; Fan YC; Zhao J; Gao S; Zhao ZH; Wang K
J Viral Hepat; 2013 Jun; 20(6):430-7. PubMed ID: 23647960
[TBL] [Abstract][Full Text] [Related]
5. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
Liu J; Tang T; Wang GD; Liu B
Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
[No Abstract] [Full Text] [Related]
6. Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.
Mazo DF; Malta FM; Stefano JT; Salles APM; Gomes-Gouvea MS; Nastri ACS; Almeida JR; Pinho JRR; Carrilho FJ; Oliveira CP
Ann Hepatol; 2019; 18(3):466-471. PubMed ID: 31054980
[TBL] [Abstract][Full Text] [Related]
7. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
[TBL] [Abstract][Full Text] [Related]
8. Correlation of cell-free DNA plasma concentration with severity of non-alcoholic fatty liver disease.
Karlas T; Weise L; Kuhn S; Krenzien F; Mehdorn M; Petroff D; Linder N; Schaudinn A; Busse H; Keim V; Pratschke J; Wiegand J; Splith K; Schmelzle M
J Transl Med; 2017 May; 15(1):106. PubMed ID: 28521774
[TBL] [Abstract][Full Text] [Related]
9. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease.
Kitamoto T; Kitamoto A; Ogawa Y; Honda Y; Imajo K; Saito S; Yoneda M; Nakamura T; Nakajima A; Hotta K
J Hepatol; 2015 Aug; 63(2):494-502. PubMed ID: 25776890
[TBL] [Abstract][Full Text] [Related]
10. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
11. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease.
Zhang RN; Pan Q; Zheng RD; Mi YQ; Shen F; Zhou D; Chen GY; Zhu CY; Fan JG
Int J Mol Med; 2018 Jul; 42(1):443-452. PubMed ID: 29568887
[TBL] [Abstract][Full Text] [Related]
13. Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
Loomba R; Jain A; Diehl AM; Guy CD; Portenier D; Sudan R; Singh S; Faulkner C; Richards L; Hester KD; Okada L; Li XJ; Mimms L; Abdelmalek MF
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1867-1876.e3. PubMed ID: 30448594
[TBL] [Abstract][Full Text] [Related]
14. DNA Methylation in Nonalcoholic Fatty Liver Disease.
Hyun J; Jung Y
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143364
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Interferon Regulatory Factor 6 Alleviates Liver Steatosis and Metabolic Disorder by Transcriptionally Suppressing Peroxisome Proliferator-Activated Receptor γ in Mice.
Tong J; Han CJ; Zhang JZ; He WZ; Zhao GJ; Cheng X; Zhang L; Deng KQ; Liu Y; Fan HF; Tian S; Cai J; Huang Z; She ZG; Zhang P; Li H
Hepatology; 2019 Jun; 69(6):2471-2488. PubMed ID: 30748020
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1α promoter.
Sookoian S; Rosselli MS; Gemma C; Burgueño AL; Fernández Gianotti T; Castaño GO; Pirola CJ
Hepatology; 2010 Dec; 52(6):1992-2000. PubMed ID: 20890895
[TBL] [Abstract][Full Text] [Related]
17. Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study.
Dongiovanni P; Rametta R; Fracanzani AL; Benedan L; Borroni V; Maggioni P; Maggioni M; Fargion S; Valenti L
BMC Gastroenterol; 2010 Sep; 10():102. PubMed ID: 20825652
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
[TBL] [Abstract][Full Text] [Related]
19. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease.
Nishida N; Yada N; Hagiwara S; Sakurai T; Kitano M; Kudo M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1646-53. PubMed ID: 26875698
[TBL] [Abstract][Full Text] [Related]
20. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
